Compare GEOS & BNR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GEOS | BNR |
|---|---|---|
| Founded | 1980 | 2014 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Medical Specialities |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 90.5M | 94.4M |
| IPO Year | 1997 | 2019 |
| Metric | GEOS | BNR |
|---|---|---|
| Price | $5.72 | $8.90 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 98.5K | 4.4K |
| Earning Date | 05-07-2026 | 06-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $110,803,000.00 | N/A |
| Revenue This Year | N/A | $111.65 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $5.50 | $6.66 |
| 52 Week High | $29.89 | $41.72 |
| Indicator | GEOS | BNR |
|---|---|---|
| Relative Strength Index (RSI) | 31.36 | 42.13 |
| Support Level | N/A | $8.69 |
| Resistance Level | $9.03 | $10.00 |
| Average True Range (ATR) | 0.48 | 0.27 |
| MACD | -0.11 | -0.01 |
| Stochastic Oscillator | 8.24 | 8.03 |
Geospace Technologies Corp is engaged in designing and manufacturing sophisticated technology solutions for applications in smart water management, energy exploration, as well as industrial and Internet of Things. Its seismic equipment is used to locate, characterize, and monitor hydrocarbon reservoirs and is also marketed for vibration monitoring, security, and geotechnical uses. The company also produces non-seismic products such as Hydroconn cables, imaging equipment, remote shutoff water valves, and IoT platforms, and provides contract manufacturing services. The company's business segments includes Smart Water, Energy Solutions and Intelligent Industrial. The majority of its revenue is generated from the Energy Solutions segment.
Burning Rock Biotech Ltd is a cancer diagnostics company. The Group provides pharma research and development services, mainly cancer therapy selection tests services, companion diagnostics development services, and other service agreements with the combination of various customized tests services and analytical validation services, to pharmaceutical companies for developing new drugs for targeted therapies, immunotherapies on various types of cancers, and to hospitals for their studies on cancer diagnosis & treatment. It had three operating segments, including the Central laboratory business, the In-hospital business, & Pharma research & development services. It generates the majority of its revenue from the Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, & others.